JP2024511977A5 - - Google Patents
Info
- Publication number
- JP2024511977A5 JP2024511977A5 JP2023556755A JP2023556755A JP2024511977A5 JP 2024511977 A5 JP2024511977 A5 JP 2024511977A5 JP 2023556755 A JP2023556755 A JP 2023556755A JP 2023556755 A JP2023556755 A JP 2023556755A JP 2024511977 A5 JP2024511977 A5 JP 2024511977A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- pharmaceutical composition
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163163779P | 2021-03-19 | 2021-03-19 | |
| US63/163,779 | 2021-03-19 | ||
| PCT/US2022/020714 WO2022197900A1 (en) | 2021-03-19 | 2022-03-17 | Methods for treating cancer with anti-ilt3 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024511977A JP2024511977A (ja) | 2024-03-18 |
| JP2024511977A5 true JP2024511977A5 (https=) | 2025-03-24 |
Family
ID=83320983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023556755A Pending JP2024511977A (ja) | 2021-03-19 | 2022-03-17 | 抗ｉｌｔ３抗体によるがんの治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240317854A1 (https=) |
| EP (1) | EP4308243A4 (https=) |
| JP (1) | JP2024511977A (https=) |
| KR (1) | KR20230158057A (https=) |
| CN (1) | CN117412771A (https=) |
| AU (1) | AU2022239502A1 (https=) |
| BR (1) | BR112023018921A2 (https=) |
| CA (1) | CA3212604A1 (https=) |
| MX (1) | MX2023010825A (https=) |
| WO (1) | WO2022197900A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111712518B (zh) * | 2017-11-17 | 2025-03-25 | 默沙东有限责任公司 | 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11198731B2 (en) * | 2017-01-20 | 2021-12-14 | Exelixis, Inc. | Combinations of cabozantinib and atezolizumab to treat cancer |
| CN111712518B (zh) * | 2017-11-17 | 2025-03-25 | 默沙东有限责任公司 | 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途 |
| CN112469730A (zh) * | 2018-05-10 | 2021-03-09 | 加利福尼亚大学董事会 | 用于治疗癌症的ccl21和检查点抑制剂 |
-
2022
- 2022-03-17 WO PCT/US2022/020714 patent/WO2022197900A1/en not_active Ceased
- 2022-03-17 AU AU2022239502A patent/AU2022239502A1/en not_active Abandoned
- 2022-03-17 EP EP22772190.9A patent/EP4308243A4/en active Pending
- 2022-03-17 KR KR1020237035228A patent/KR20230158057A/ko active Pending
- 2022-03-17 CA CA3212604A patent/CA3212604A1/en active Pending
- 2022-03-17 BR BR112023018921A patent/BR112023018921A2/pt unknown
- 2022-03-17 CN CN202280036448.1A patent/CN117412771A/zh active Pending
- 2022-03-17 MX MX2023010825A patent/MX2023010825A/es unknown
- 2022-03-17 JP JP2023556755A patent/JP2024511977A/ja active Pending
- 2022-03-17 US US18/550,537 patent/US20240317854A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180036395A1 (en) | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies | |
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| TW202038957A (zh) | 抗體-藥物結合物與激酶抑制劑之組合 | |
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| TWI818120B (zh) | 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療 | |
| JP2019194233A (ja) | 腫瘍性疾患のための治療 | |
| JP2021534094A5 (https=) | ||
| US20250049940A1 (en) | Combined Use of Anti-TROP-2 Antibody-drug Conjugate and other Therapeutic Agents | |
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| WO2020249018A1 (zh) | 治疗驱动基因阳性肺癌的联用药物组合物 | |
| WO2020233602A1 (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| JP2023525048A (ja) | 膵臓がんおよび他の固形腫瘍を処置するための方法 | |
| JP2024511977A5 (https=) | ||
| BR112020026382A2 (pt) | combinações de poziotinibe com um anticorpo anti-her1, her2 ou her4 e métodos de uso das mesmas | |
| JP2017515843A (ja) | 抗ｅｇｆｒ治療薬の投与量および投与 | |
| WO2025103377A1 (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| CN109793892B (zh) | 一种抗pd-1抗体在制备治疗食管癌的药物中的用途 | |
| TW202045175A (zh) | Ｓｕｍｏ-活化酶抑制劑及檢查點抑制劑之投與 | |
| TWI671072B (zh) | 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合 | |
| WO2019129168A1 (zh) | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 | |
| WO2019096233A1 (zh) | 免疫治疗剂、核苷类抗代谢物和铂类联合在制备治疗肿瘤的药物中的用途 | |
| Naqash et al. | 720TiP Phase I, open-label, first-in-human (FIH) study of JZP815 in advanced or metastatic solid tumors harboring mitogen-activated protein kinase (MAPK) alterations | |
| CN121622921A (zh) | Her2 adc药物组合物及其用途 | |
| CN111821304A (zh) | 酪氨酸激酶抑制剂联合长春碱类药物在制备预防或治疗肿瘤疾病的药物中的用途 |